决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Cancer and diabetes co-occurrence: A national study with 44 million person-years of follow-up.
我们发现,在研究期间诊断的24种最常见癌症中,有21种在糖尿病患者中的发病率最高,糖尿病患者中的超额风险介于11%(非霍奇金淋巴瘤)至236%(肝癌)之间。
癌症新发病例数逐年增加,糖尿病患病率也随时间显著上升。由于这两种疾病各自都很常见,且一种疾病可能增加另一种疾病的风险,因此个体同时患有癌症和糖尿病并不罕见。在本手稿中,我们使用覆盖近五百万个体、超过4400万人年随访的全国性糖尿病(Virtual Diabetes Register)和癌症(New Zealand Cancer Registry)数据,考察了全国糖尿病患病队列中癌症的发生情况。我们按癌症类型分别对Aotearoa New Zealand最常见的24种癌症完成了这一分析,然后比较了糖尿病患者与非糖尿病患者中癌症的发生情况。我们发现,在我们研究期间诊断的24种最常见癌症中,有21种在糖尿病患者中的癌症发生率最高,糖尿病患者中的超额风险介于11%(non-Hodgkin's lymphoma)至236%(liver cancer)之间。糖尿病患者与非糖尿病患者之间发病率差异最大的癌症往往位于内分泌系统或胃肠道系统,和/或与肥胖有很强的关系。然而,从绝对意义上说,由于breast、colorectal和lung cancers的数量庞大,预防糖尿病患者中较为温和的超额癌症风险(分别为16%、22%和48%)将带来人群癌症总负担的大幅总体下降。我们的发现强化了这一事实:糖尿病预防活动也是癌症预防活动,因此必须同步优先推进并配置资源。
The number of new cases of cancer is increasing each year, and rates of diabetes mellitus are also increasing dramatically over time. It is not an unusual occurrence for an individual to have both cancer and diabetes at the same time, given they are both individually common, and that one condition can increase the risk of the other. In this manuscript, we use national-level diabetes (Virtual Diabetes Register) and cancer (New Zealand Cancer Registry) data on nearly five million individuals over 44 million person-years of follow-up to examine the occurrence of cancer amongst a national prevalent cohort of patients with diabetes. We completed this analysis separately by cancer for the 24 most commonly diagnosed cancers in Aotearoa New Zealand, and then compared the occurrence of cancer among those with diabetes to those without diabetes. We found that the rate of cancer was highest amongst those with diabetes for 21 of the 24 most common cancers diagnosed over our study period, with excess risk among those with diabetes ranging between 11% (non-Hodgkin's lymphoma) and 236% (liver cancer). The cancers with the greatest difference in incidence between those with diabetes and those without diabetes tended to be within the endocrine or gastrointestinal system, and/or had a strong relationship with obesity. However, in an absolute sense, due to the volume of breast, colorectal and lung cancers, prevention of the more modest excess cancer risk among those with diabetes (16%, 22% and 48%, respectively) would lead to a substantial overall reduction in the total burden of cancer in the population. Our findings reinforce the fact that diabetes prevention activities are also cancer prevention activities, and must therefore be prioritised and resourced in tandem.
MEMBER ACCOUNT
登录成功会直接打开下一页。